Want to join the conversation?
$SIAL's selling, general and administrative expenses for 3Q15 increased by $18MM from last year, primarily due to inclusion of SG&A resulting from acquisition of Cell Marque on Oct. 31, 2014 and higher incentive compensation costs, partially offset by lower SG&A costs resulting from translation of functional currencies to the USD.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.